Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.

Date
2021
Author
Uema, Deise
Boegemann, Martin
Krissel, Heiko
Chen, Huanyu
Wagner, Volker Jean
Fizazi, Karim
Gonzalez del Alba, Aranzazu
Mustafa, Ozguroglu
Skoneczna, Iwona Anna
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/175250
https://doi.org/10.1200/jco.2021.39.15_suppl.tps5093
Collections